Learn from the best in healthcare. We present you with real-time developments and actionable strategies. Register to ask your immediate questions and to access our slides.
In 2014 the healthcare industry saw fundamental change in how health plans approach the market, provider consolidation in many areas, a focus on quality-based payments, unprecedented growth in consumer liability for the cost of chronic illness, and a slowing in the rise in healthcare costs.
In the payment and delivery reform landscape, bundled payments are emerging as a promising model. Medicare, Medicaid, and commercial payers are adopting bundled acute and post-acute care payments to align cost and quality incentives across an entire episode of care.
Providing patient access to investigational treatments outside of clinical trials is once again in the spotlight of media scrutiny. Earlier this year, social and popular media attention pressured one company to provide an investigational treatment to a young cancer patient. Then, states began debating and passing “Right to Try” bills to set up a new pathway to allow access to investigational drugs.
With the rise in state-based and regional comparative effectiveness research (CER), local CER programs like the New England Comparative Effectiveness Review Public Advisory Council (CEPAC) have become increasingly influential in payer decision making.
The biopharma/device merger and acquisitions space is proving extremely lively in 2014, and an early read on the magnitude of risk is essential for effectively triaging deal flow.
Patient engagement has become a new buzz word in drug development. Nevertheless, much uncertainty still exists among stakeholders on how and when to best engage patients in the product development and approval processes.
Debbie Lucas from Avalere Health will discuss the emerging and complex quality landscape from the perspectives of healthcare stakeholders, including providers, health systems, health plans and others across the industry.